Members of the Hematologic Malignancies Sections of the John Theurer Cancer Center at Hackensack University Medical Center co-authored the following presentations at the 2008 American Society of Hematology meetings:

BLOOD AND MARROW TRANSPLANTATION

2797 Michele L. Donato, MD1*, Angela Prann, MPH2*, Anna Ullrich, RN3*, Tatyana Feldman, MD4, Stuart L. Goldberg1, Andre Goy, MD5, Aisha Masood, MD1*, Andrew L. Pecora, MD6, David S. Siegel1* and Scott D. Rowley, MD, FACP7 Outcome of Patients with Myeloproliferative Disorders Treated with Allogeneic Hematopoietic Stem Cell Transplantation Read Abstract >>

2913 Jacalyn Rosenblatt, Baldev Vasir, Zekui Wu, Corrine Zarwan, Richard Stone, Adam Bissonnette, Thea M Friedman, Donna Neuberg, Natalya Rozenveyn, Brett Glotzbecker, James D. Levine, Robin Joyce, Vassiliki Boussiotis, Dimitrios Tzachanis, Dimitrios Spentzos, Panagiotis Konstantinopoulos, Donald Kufe, and David Avigan Adoptive T Cell Therapy Using Educated T Cells Generated by the Sequential Stimulation with DC/Tumor Fusion Cells and Anti-CD3CD28 Read Abstract >>

3517 Stacey L Fanning, Stephanie A Berger, Kristin Vazzana, Loise N Gichuru, Robert Korngold, and Thea M Friedman Vβ Spectratype-guided Separation of Graft-Versus-Host Disease and Graft-Versus-Leukemia Effects in a MHC-Matched miHA-Mismatched Mouse Model of Hematopoietic Stem Cell Transplantation Read Abstract >>

LEUKEMIA AND MYELODYSPLASIA

636 Stuart L Goldberg, MD1, Nikita Mody-Patel, PharmD2* and E. R Chen, MPP3* Clinical and Economic Consequences of Myelodysplastic Syndromes in the United States: An Analysis of the Medicare Database Read Abstract >>

2128 Delong Liu, MD, PhD1*, Yousif Matloub2*, Jaydip Mukhopadhyay2*, David Liu2* and Stuart L Goldberg3 Dasatinib Is Associated with Rapid and Durable Complete Hematologic Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Read Abstract >>

3651 Mark Kirschbaum1, Ivana Gojo2, Stuart L Goldberg3, Lisa Kujawski4*, Ehab Atallah5*, Peter Marks6, Jose Garcia-Vargas7*, Syed Rizvi7, Donna Di Gravio7*, Janet Ahern7* and Jean-Pierre Issa8 Phase I Study of Vorinostat in Combination with Decitabine in Patients with Relapsed or Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome Read Abstract >>

4254 Andrey Zaritskey, Giuliana Alimena, Lech Konopka, Jila Shamsazar, Priscille M. Bourquelot, Muhammad Jalaluddin, Martha Li, Anna Turkina, Gert J. Ossenkoppele, Stuart L. Goldberg, and Bayard Powell A Phase II Study of Oral Panobinostat (LBH589) for Chronic Phase Chronic Myeloid Leukemia (CML) with Resistance to 2 BCR-ABL Tyrosine Kinase Inhibitors

5084 Guillermo Garcia-Manero, Lewis B. Silverman, Ivana Gojo, Laura Michaelis, Simrit Parmar, Stuart L Goldberg, Hagop M. Kantarjian, Jose Garcia-Vargas, Syed Rizvi, Karl Heath, and Azra Raza A Randomized Phase IIa Study of Vorinostat in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes: Preliminary Results

LYMPHOMA

261 Owen A O’Connor, Barbara Pro, Lauren Pinter-Brown, Leslie Popplewell, Nancy Barlett, Andrei Shustov, Mary Jo Lechowcz, Kerry Savage, Bertrand Coiffer, Eric Jacobsen, Pier Luigi Zinzani, Andre Goy, Jasimine Zain, Shannon Wilroy, Molly Patterson, Adam Boyd, Michael E Saunders, Pblo Cagnoni, Steven M Horwitz. PROPEL: A Multi-center Phase 2 Open-Label Study of Pralatrexate (PDX) with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma Read Abstract >>

1563 John Gerecitano1, O. O'Connor2, H. Van Deventer3*, J. Hainsworth4, J. Leonard5, A. Goy6, B. Afanasyev7*, M. Chen8*, K. Saikali8*, M. G Conlan8*, R Escandon8* and A Wolff8* A Phase I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 Administered on Days 1 and 15 Every 28 Days without and with Prophylactic G-CSF in Non-Hodgkin or Hodgkin Lymphoma Read Abstract >>

3051 Jorge Romaguera, MD1, Luis Fayad1, Peter McLaughlin, MD1*, Barbara Pro, MD1, Maria Alma Rodriguez, MD1, Michael Wang, MD1*, Pamela Weaver, RN1*, Kimberly Hartig1*, Larry Kwak, MD, PhD1*, Tatyana Feldman, MD2, Judy Smith, RN2*, Peggy Ford, RN2*, Stuart Goldberg, MD2*, Andrew Pecora, MD2* and Andre Goy, MD2* Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/ Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma Read Abstract >>

4944 Anne Beaven, Thomas C. Shea, Dominic T Moore, Tatyana Feldman, Anastasia Ivanova, Madlyn Ferraro, Peggy Ford, Judy Smith, and Andre Goy A Phase I Study of Bortezomib (Velcade®) Plus 90yttrium Labeled Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NHL)

MULTIPLE MYELOMA

864 Sundar Jagannath, MD1, Ravi Vij, MD2*, A. Keith Stewart, MBChB3, George Somlo, MD4*, Andrzej Jakubowiak, MD, PhD5, Tony Reiman, MD6, Suzanne Trudel, MD7*, Jessica Taylor, BA8*, Diana Fuhrman, BSN8*, Scott Cruickshank, MS8*, Richard Schwartz, MD8*, Lori Kunkel, MD8*, David Siegel, MD, PhD9 and The Multiple Myeloma Research Consortium (MMRC)10* Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM) Read Abstract >>

865 Ravi Vij, MD1*, Michael Wang, MD2*, Robert Orlowski, MD, PhD2*, A. Keith Stewart, MBChB3, Sundar Jagannath, MD4, Vishal Kukreti, MD, FRCPC5, Jessica Taylor, BA6*, Diana Fuhrman, BSN6*, Scott Cruickshank, MS6*, Richard Schwartz, MD6*, Lori Kunkel, MD6*, David Siegel, MD, PhD7 and The Multiple Myeloma Research Consortium (MMRC)8* Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM) Read Abstract >>

871 Donna Weber1, Ashraf Z. Badros2, Sundar Jagannath3, David Siegel4, Victoria Richon5*, Syed Rizvi5, Jose Garcia-Vargas5*, David Reiser5* and Kenneth C. Anderson6* Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: Early Clinical Experience Read Abstract >>

1740 Susanna Jacobus1*, Shaji Kumar2, Natalie Scott Callander3, Rafat Abonour4, Rafael Fonseca5*, David Siegel6, Philip Greipp7* and S.Vincent Rajkumar2 Effect of Venous Thrombotic Events on Overall Survival in Multiple Myeloma: Analysis of Thrombotic Events Occurring in E4A03A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma, a Trial Coordinated by the Eastern Cooperative Oncology Group (ECOG) Read Abstract >>

2774 Jeffrey Lee Wolf1*, David Siegel2, Jeffrey Matous3, Sagar Lonial4*, Hartmut Goldschmidt5, Stefan Schmitt6*, Ravi Vij7, Margarida De Malgalhaes-Silverman8*, Rafat Abonour9, Muhammad Jalaluddin10*, Martha Li11*, Katharine Hazell12*, Priscille M. Bourquelot12, Maria-Victoria Mateos13*, Kenneth C. Anderson14, Andrew Spencer15*, Jean-Luc Harousseau16 and Joan Bladé17 A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma Read Abstract >>

2781 David Siegel1, Orhan Sezer2*, Jesus F. San Miguel3*, Maria-Victoria Mateos3*, Ian Prosser4, Michele Cavo5*, Muhammad Jalaluddin6*, Katharine Hazell7*, Priscille M. Bourquelot7 and Kenneth C. Anderson, MD8 A Phase IB, Multicenter, Open-Label, Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma Read Abstract >>

3178 William G. Wierda, MD1*, R. Chen, MD2*, William Plunkett, MD3*, Steven Coutre, MD4, Ashraf Z. Badros, MD5, Leslie Popplewell, MD6, David Siegel, MD7, Rajni Sinha, MD8*, Donald Harvey, Pharm., D.9*, Judith Fox, PhD10*, Kristi Mahadocon11*, Peggy Kegley11* and Mary G. Bolton, MD, PhD11* A Phase 1 Trial of SNS-032, a Potent and Specific CDK 2, 7 and 9 Inhibitor, in Chronic Lymphocytic Leukemia and Multiple Myeloma Read Abstract >>

3697 Jonathan Kaufman, MD1*, Ruben Niesvizky, MD2, Edward A. Stadtmauer, MD3*, Asher Chanan-Khan, MD4, David Siegel, MD, PhD5, Heather Horne6*, Nick Teoh, PhD6*, Matthew J. Leoni, MD6*, William A Wegener, MD, PhD6 and David M. Goldenberg, ScD, MD6* First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma Read Abstract >>

3702 Jesús F San Miguel1, Meletios A Dimopoulos, MD2, Edward A. Stadtmauer, MD3*, S. Vincent Rajkumar, MD4*, David Siegel5, Marie-Laure Bravo6*, Marta Olesnyckyj7*, Robert D. Knight, MD7, Jerome B. Zeldis, MD7, Jean-Luc Harousseau8 and Donna M. Weber9 Longer Duration of Treatment and Maintenance of Best Response with Lenalidomide and Dexamethasone Prolongs Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma Read Abstract >>

3705 David Siegel1, Donna Weber, MD2, Constantine S. Mitsiades, MD, PhD3, Syed Rizvi4, Jose Garcia-Vargas4*, Jason Howe5*, David Reiser4*, Kenneth C. Anderson, MD6* and Paul Richardson, MD7 A Phase I Study of Vorinostat in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Read Abstract >>

5129 Shaji Kumar, Lijun Zhang, Angela Dispenzieri, Sagar Lonial, Rafat Abonour, Leonard Heffner, Natalie Scott Callander, David Siegel, Morie Gertz, Robert Kyle, Philip R. Greipp, and S. Vincent Rajkumar Response Duration with Initial Therapy Is a Major Predictor of Overall Survival in Multiple Myeloma: Analysis from Multiple Phase III ECOG Clinical Trials

5135 Afsheen N Iqbal, Quan Le, Rajeev Motiwala, Leila J Clay, Tej Motiwala, Nikoletta Lendvai, David S. Siegel, and Stuart L Goldberg Guillain-Barre Syndrome Complicating Multiple Myeloma

5188 Edward A. Stadtmauer, David Siegel, Dan T Vogl, James Stinnett, Geetha Narayanan, P.P. Bapsy, Trivadi Ganesan, Minish Jain, Sripada V.S.S Prasad, Douglas S McNair, Linda DeYoung, Alice Lane, and Bruce Silver A Phase 1 Trial of Fluphenazine HCl (Fz), a Serotonin Antagonist, in Relapsed and Refractory Multiple Myeloma

5218 David Siegel and Karly Olivo Clinical Efficacy of Oral Vorinostat Combined with Lenalidomide and Dexamethasone in a Patient with Refractory End-Stage Multiple Myeloma – a Patient Case Study